Sitting by the pool.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree.
Everyone knows when the shorts start whining, the stock is about to run.
I'm sure it will be for a bit. There's something larger taking place. I expect an announcement on pipeline/M&A with zomedica acquiring or buyout. It feels like there is something brewing.
worth a shot.
So I called Millervet and played dumb looking for product information.
The CSR stated something was going with Zomedica. The miller team was instructed not to share any Truforma info unless a licensed veterinarian registered with Miller. She did offer that there has been a ton of interest in the product, having to repeat herself many times per day.
If there are any Miller registered vets on this forum, would they mind calling miller and reporting back what they learn?
Smells of a BUYOUT.
Yes, they will.
A2Z must be Nostradamus.
Most interesting part of this press to support truforma or products acquired by zomedica.
BUY BUY BUY.
Zomedica to Build Direct Sales Force for TRUFORMA® Platform
April 15, 2021 06:01 ET | Source: Zomedica Corp.
ANN ARBOR, Mich., April 15, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it intends to expand its direct sales organization while phasing out its distributor-based sales efforts.
Robert Cohen, Chief Executive Officer of Zomedica, commented: “As TRUFORMA®’s market presence grew, we intended to transition from a distributor-based sales model to a direct sales organization. However, due to anticipated changes at our current distributor that we believe have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization. While this effort may slow initial sales of TRUFORMA®, we have taken this action now to avoid any disruption to our customers and to provide a stronger foundation on which to build the marketing and sales of both TRUFORMA® and any future products developed or acquired by Zomedica.”
Zomedica currently employs eight direct field sales personnel, supported by two regional managers, a Vice President of Sales, and a Chief Commercial Officer. Brük Herbst, Chief Commercial Officer of Zomedica, commented: “During my time as Head of Sales & Marketing at IDEXX, I saw the value and impact of a direct sales organization. A direct sales force will significantly improve our ability to serve our customers and to sell our products in the veterinary market in the longer term. We are fortunate that we have the financial strength at Zomedica to make this transition, and look forward to building a quality sales force to match the excellent quality of TRUFORMA®.”
For additional information regarding TRUFORMA®, please click on the TRUFORMA® tab at the top of the home page on the Zomedica website (www.zomedica.com).
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Reader Advisory
Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
PCG Advisory
Kirin Smith, President
ksmith@pcgadvisory.com
+1 646.823.8656
8 people on LinkedIn in sales and/or biz dev roles. I won't oust their names here for respect of people's privacy, but it's readily available on the www3.
Interestingly, they pulled their pipeline from the website. I've emailed Bruk Hurst, Bonnie Bragdon in addition to Kirin Smith, their investor relations contact. They're all usually pretty responsive in the past. Crickets. Have at least 6 emails out on the pipeline and can't get a response. Not asking to divulge material information. Just why did they remove it from the website.
Anything is plausible but why do you think buyout?
So JNJ terminated the PUR1800 license. Interesting. Is anyone close enough to have information on whether this is a result of the product or JNJ cutting expenses?
As of February 26, 2021 they had $277.5M of cash and cash equivalents
https://www.sec.gov/Archives/edgar/data/1684144/000117184321001380/exh_991.htm
Only you can answer that question. Personally, I haven't sold a share.
$277M cash on hand, now part of S&P Pharma 500 ETF $XPH, Truforma delivered ahead of the committed commercialization date. ZM-017 and ZM-022 patent decisions are due early summer. There's a lot to like long on this stock.
Any stock that was pumped in the Reddit crowd has been heavily shorted the last three weeks. Most of the Reddit companies are pure dogshit except $zom. $277M cash on hand, flagship product launched within the last 30 days, proven management team, and solid pipeline with more revenue potential than truforma. I'm playing with house money and will ride this until north of $10, which I believe is closer than any of us would guess.
It's heavily shorted which is a shame. It's going to take sales updates and/or patent and pipeline updates to reverse this trend. Patent decisions on zm-017, zm-022 are due in June.
$277M cash on hand, truforma is live, added to the xph SPDR EFT.
There's a lot to like long-term on Zomedica.
limit sell set .
Look at the 8k and press release from 3/16.
Market Date Short Volume Total Volume
(MM Shares) Short Volume Ratio
2021-03-17 27,636,940 119.91 23.05
2021-03-16 52,666,019 181.74 28.98
2021-03-15 16,370,981 103.85 15.76
2021-03-12 15,012,552 101.73 14.76
2021-03-11 15,513,561 44.72 34.69
2021-03-10 22,468,027 65.72 34.19
2021-03-09 15,072,738 61.13 24.66
2021-03-08 20,989,260 59.04 35.55
2021-03-05 47,823,884 123.84 38.62
2021-03-04 29,007,771 79.64 36.
ZOM / Zomedica Pharmaceuticals Corp. Short Volume Ratio
Market Date Short Volume Total Volume
(MM Shares) Short Volume Ratio
2021-03-16 52,666,019 177.05 29.75
2021-03-15 16,370,981 103.85 15.76
2021-03-12 15,012,552 101.73 14.76
2021-03-11 15,513,561 44.72 34.69
2021-03-10 22,468,027 65.72 34.19
2021-03-09 15,072,738 61.13 24.66
2021-03-08 20,989,260 59.04 35.55
2021-03-05 47,823,884 123.84 38.62
2021-03-04 29,007,771 79.64 36.42
2021-03-03 22,120,150 64.92 34.07
Heavy short sale pressure today could see it in the volumes. I’m waiting to see the numbers refresh on fintel.io and I’ll share here for those who don’t have a subscription. On that same vein nasdaq was green but every meme stock was red. Mm want that stimmy money. Manipulation.
Im interested to learn more. I tried to google and couldn’t find anything. Is there an article you can link that discusses the changes?
What am I missing on the March 19th date?
Ha Who me? Never been called Shamwow before.
ZM-017 and ZM-20 patent decisions due soon
Truforma in 30 or less days. Multiple additional catalysts with patent application responses due on zm-17 and zm-20 this year. $277.5M cash on hand. Very strong penny stock here I’m extremely bullish.
Total speculation here. I think it would make a lot of sense for Zomedica to buy Seraph Biosciences. The patent application for ZM-020 due within the next few months.
They have the cash.
https://www.globenewswire.com/news-release/2018/05/10/1500121/0/en/Zomedica-Signs-Agreement-With-Seraph-Biosciences-for-Innovative-Veterinary-Point-of-Care-Diagnostic.html
It just ran 1000% in 6 weeks, just catching its breath before the next monster leg up. They raised $200M to add to the $90M+ they had on the books. All technical indicators look buy to strong buy, RSI has finally settled. Several catalysts on the short-term horizon. It's a good time to get in on a discount. With the amount of institutional money joining at $2 this won't be here for long. I suspect we'll get a pop for Truforma, and another pop mid-summer when either the UTI or cancer BAW diagnostic patents are approved. This company is starting to look a lot like Heska or Zoetis in their early years. Or Adaxis if folks remember that company. Adaxis was actually acquired by Zoetis in 2018. Follow the smart money there's plenty here.
Great day to pad the positions, hopefully, everyone got a few cheapies. Short sellers Sabby and Citadel are out dumped 100% of their positions! The attraction of BlackRock and Vanguard and the pure volume of this stock/rise in price scared them off.
Nearly $300M in cash, additional patent applications due soon, Truforma launching in 41 days. It's a good time to be holding Zom. The future is bright.
Well, folks, Zomedica has almost $300M in cash. Truforma launches in 42 days. They're using Miller distribution to get their products to market. Same distribution partner utilized by the highly respected companies like Zoetis and Heska(also Qorvo partner). Robert Cohen is aggressive. I would not be surprised if they bought into another late-stage pet product or went on a hiring spree to speed up the UTI and Cancer diagnostic products. Both of those patent applications are due this year. Everything on this company looks solid. Its not a meme stock as much as the pump has ensued. Make sure to leave some on the table because in 2-3 years this will be a 20-30B market cap company.
Headed on up to the east side.
I guess no imminent buyout. Not necessarily a bad thing but it annoying when you're told X and they deliver Y.
Sumit is an engineer, he's not a CEO. This company could flourish if brought in a proper CEO.
Love to see current insiders buying more shares at today's prices, couldn't be a stronger indication of great things to come. Buy on the dip today, may not see another day under $2.50 by the time Truforma launches. 42 days for anyone who's counting.
Truforma launches in 46 days.
High five money making time, watch this go!!
No one, it wasn't a public offering.
The direct offering is a bullish sign. Public offering bad, direct offering is good. Institutional investors are buying in at roughly a $2B market cap @$1.90. They have access to inside information and they want in. Consider this ZOM will have $100M more cash on the balance sheet than $HSKA their nearest competitor. New highs on the horizon. $10 is not unreasonable imho
Who sold on yesterday’s fear?
Welcome aboard.
This healthy move today $5 before we know. Congratulations Carl you called $5 first and a long time ago. Congratulations to all the longs.
Don’t sell on fear, never sell on fear. Truforma launches in 49 days. Will be over $5 by April 1st. $173.5 of institutional dollars added at $1.90. This will run like $ocgn $bngo $sens and so many others. Hold the line.